ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC) Options
In Segment C, individuals will acquire ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually condition progression or the individuals are unable to tolerate the study drugs.- "Our study unveiled the critical purpose with the KLF16/MYC regulatory axis in modulatin